PROTAC CYP1B1 degrader-1

• UNSPSC Description:

  PROTAC CYP1B1 degrader-1 (Compound 6C), a α-naphthoflavone chimera derivative, is able to eliminate cytochrome P450 (CYP)1B1-mediated agent resistance via targeted CYP1B1 degradation, with IC50s of 95.1 and 9838.6 nM for CYP1B1 and CYP1A2, respectively. PROTAC CYP1B1 degrader-1 can be used for the research of CYP1B1-overexpressing prostate cancer[1].

• Target Antigen:

  Cytochrome P450; PROTACs

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease;PROTAC

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/protac-cyp1b1-degrader-1.html

• Solubility:

  DMF : 10 mg/mL (ultrasonic)

• Smiles:

  COC1=CC=C(C2=C3OC(C4=CC=C(C=C4)C5=CN(N=N5)CCCCCCOC6=CC=CC7=C6C(N(C7=O)C8CCC(NC8=O)=O)=O)=CC(C3=CC(OC)=C12)=O)OC

• Molecular Weight:

  785.80

• References & Citations:

  [1]Li Zhou, et al. Design and synthesis of α-naphthoflavone chimera derivatives able to eliminate cytochrome P450 (CYP)1B1-mediated drug resistance via targeted CYP1B1 degradation. Eur J Med Chem. 2020 Mar 1;189:112028.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2411389-67-6